期刊文献+

P-gp和细胞表面分化抗原在ALL中表达的关系和临床意义

The Relationship and Clinical Significance between P-gp and Cell Surface Differentiation Antigens in Acute Lymphoblastic Leukemia
原文传递
导出
摘要 目的探讨初治急性淋巴细胞白血病(ALL)中P-糖蛋白(P-gp)与细胞表面分化抗原表达的关系及意义。方法应用流式细胞术对64例初治ALL患者进行P-gp及免疫表型的检测。结果 P-gp的阳性表达率为45.3%,CD34为59.4%,My+ALL为31.3%,其中CD13阳性率最高,为20.3%。P-gp与预后呈负相关(P<0.05),CD34+、My+ALL与CD34-、My-ALL的CR率差异均无统计学意义(P>0.05)。P-gp+组中CD34的表达显著高于P-gp-组(P<0.05),其他中晚期抗原表达差异无统计学意义。P-gp与CD34协同表达则CR率更低(52.2%vs90.0%)。结论 P-gp的表达在初治ALL患者中具有重要的预后意义。P-gp的过度表达与CD34有关,P-gp+/CD34+的ALL属于一种预后不良的临床亚型。 Objective To explore the relationship and significance between P-glycoprotein and cell surface differentiation antigens in ALL.Methods FCM was used to detect the expression of P-glycoprotein and immunophenotype in 64 de novo ALL patients.Results The positive rates of P-gp,CD34 and Ly+ were 45.3%,59.4% and 31.3%,respectirely.Compared to other surface antigens,CD13(20.3%) was the common one in My+ ALL.P-gp was negative correlation with prognosis in ALL(P0.05).No statistical difference in the CR rates were found between CD34+,My+ ALL and CD34-,My-ALL(P0.05).The positive rate of CD34 in P-gp+ patients was higher than that in P-gp patients(P0.05).The CR rate in P-gp+/CD34+ patients was lower than that in P-gp-/CD34-patients(52.2% vs 90.0%).Conclusions It is suggested that the expression of P-gp possesses prognostic significance in ALL.The overexpression of Pgp is related to CD34 and ALL patients with P-gp+/CD34+ predicts a poor prognosis.
出处 《热带医学杂志》 CAS 2010年第12期1405-1406,1414,共3页 Journal of Tropical Medicine
关键词 急性淋巴细胞白血病 P-糖蛋白 CD34 细胞表面分化抗原 预后 acute lymphoblastic leukemia P-gp CD34 cell surface differentiation antigens prognosis
  • 相关文献

参考文献7

二级参考文献22

  • 1赵红雯,杨继红.儿童急性淋巴细胞白血病的免疫表型分析[J].基层医学论坛,2004,8(10):875-876. 被引量:1
  • 2舒文秀,陈燕.急性淋巴细胞白血病免疫分型的特点及其临床意义[J].临床血液学杂志,2005,18(2):103-106. 被引量:16
  • 3栾凤君,杨纯正,邵晓枫,刘炳仁,李滨,卞寿庚.100例急性白血病患者多药耐药性检测分析[J].中华肿瘤杂志,1994,16(5):360-363. 被引量:13
  • 4Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemia. European Group for the Immunological characterization of Leukemias(EGIL) [ J]. Leukemia, 1995,9:1783 - 1786.
  • 5Huh YO, Ibrahim S.Immunophenotypes in adult acute lymphoblastic leukemia: Role of flow cytometry in diagnosis and monitoring of disease[J]. Hematol Oncol Chn North Am, 2000,14:1251 - 1265.
  • 6Preti HA, Huh YO, Brien O, et al. Myeloid markers in adult acute lymphoblastic leukemia [ J ]. Cancer, 1995, 76 (12) : 1564- 1578.
  • 7Speechia G, Debellis G, Mestice A, et al. Myeloid markers in adult tymphoblastic leukemia [ J ]. Br J Hematol, 1996, 93 (suppl 2) :61.
  • 8Thomas X, Archimbaud E, Charrin C, et al. CD34 expression is associated with major adverse prognostic factors in adult lymphoblasfic leukemia[J]. Leukemia, 1995,9(4) : 249 - 253.
  • 9张之南,血液病诊断及疗效标准(第2版),1998年,184页
  • 10Marie JP,zittoun R,Sikic BI.Multidrug resistance(mdr1) gene expression in adult acute leukemias:correlations with treatment outcome and in vitro drug sensitivity[J].Blood,1991,78(3):586-592.

共引文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部